Basic information Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Antipyretic analgesics >  Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) >  Iguratimod

Iguratimod

Basic information Safety Related Supplier
Iguratimod Basic information
Iguratimod Chemical Properties
  • Melting point:238.0 to 242.0 °C
  • Boiling point:580.6±60.0 °C(Predicted)
  • Density 1.52±0.1 g/cm3(Predicted)
  • pka5.58±0.20(Predicted)
Iguratimod Usage And Synthesis
  • Description

    In August 2011, China’s State FDA approved Simcere Pharmaceutical Group’s new drug application for iguratimod (T-614), a disease modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Preclinical in vivo studies indicated that iguratimod was effective in an established adjuvant-induced arthritis model (ED40=3.6 mg/kg) in rats and also efficacious in a type II collagen-induced arthritis model in DBA/1J mice at 30 mg and 100 mg/kg.

  • OriginatorToyama (Japan)
  • UsesIguratimod acts as an anti-inflammatory agent, used primarily in the treatment of rheumatoid arthritis.
  • brand nameIremod
  • Clinical UseIguratimod, which was discovered by Toyama Pharmaceuticals and jointly co-developed with Eisai in Japan, was approved by the PMDA (Pharmaceuticals and Medical Devices Agency) of Japan on June 29, 2012 for the treatment of rheumatoid arthritis. This drug was also independently developed by Simcere Pharmaceutical Group and is marked as Iremod® in China. The drug exhibited inhibitory effects on granuloma inflammation, and was shown to be efficacious for the prevention of joint destruction in adjuvant arthritis.
  • Chemical SynthesisSeveral synthesis of iguratimod have been published, the most likely scale synthesis, which does not require chromatographic purification, is described in the scheme.The synthesis began with commercially available 3-nitro-4-chloro anisole (78) which was reacted with potassium phenoxide (generated from phenol and potassium t-butoxide at 110 oC) to provide the corresponding nitrophenyl ether which was subsequently reduced and sulfonylated to furnish sulfonamide 79. Next, this diphenyl ether was subjected to a Friedel-Crafts reaction with aminoacetonitrile hydrochloride which gave rise to aminomethylacetophenone 80 in 90% yield. This aminoketone was then formylated with formic trimethylacetic anhydride 81 at room temperature to afford formamide 82 in 91% yield, and this material was immediately subjected to O-demethylation conditions with aluminum trichloride and sodium iodide in acetonitrile to give the phenol 83 in 95% yield. Finally, treatment of the aminomethyl acetophenone phenol 83 with N,N-dimethylformamide dimethylacetal in DMF at low temperatures furnished iguratimod (XII) in 87% yield.

Iguratimod(123663-49-0)Related Product Information
IguratimodSupplierMore
  • Company Name:Shanghai Fulland Pharmaceuticals Ltd Gold
  • Tel:18964441746 021-50432069-
  • Email:sales2@fullandpharma.com
  •  
  • Company Name:China fortune way company Gold
  • Tel:15501136739 010-84660735-
  • Email:rnd@sinopharmintl.com
  •  
  • Company Name:Shanghai Boyle Chemical Co., Ltd.
  • Tel:
  • Email:sales@boylechem.com
  •  
  • Company Name:J & K SCIENTIFIC LTD.
  • Tel:400-666-7788 010-82848833-
  • Email:jkinfo@jkchemical.com;market6@jkchemical.com
  •  
  • Company Name:Chembest Research Laboratories Limited
  • Tel:021-20908456-
  • Email:sales@BioChemBest.com
  •